Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence.
Effectiveness
Golimumab
Persistence
Real-world evidence
Ulcerative colitis
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
18
08
2018
revised:
21
10
2018
accepted:
04
11
2018
pubmed:
18
12
2018
medline:
19
9
2019
entrez:
18
12
2018
Statut:
ppublish
Résumé
Biologics against tumor necrosis factor (anti-TNF) have dramatically changed the management of moderate-to-severe ulcerative colitis (UC). In pivotal clinical trials, golimumab showed efficacy as induction and maintenance therapy in anti-TNF naïve UC patients. However, confirmatory data on effectiveness in the real world setting are needed. to summarize recent evidence on the effectiveness of golimumab in observational real-world studies. A literature search was conducted using Medline, Embase, and congresses databases for English language articles or abstracts on the effectiveness of golimumab published between January 1, 2014 and May 15, 2018. Pooled short-term (6-14 weeks) and mid- and long-term (24-54 weeks) clinical response and remission rates were calculated. 24 abstracts were included; of those 8 were published full-text articles and 16 were abstracts from medical conferences. Overall, pooled short-term clinical response and remission rates were 59.3% (range 35-85.5%; 13 studies; 1429 patients) and 35.9% (range 14-51.7%; 9 studies; 666 patients), respectively. Pooled mid- and long-term clinical response and remission rates were 60.3% (range 37.1-89.5%; 4 studies; 356 patients) and 39.2% (range 12-84%; 8 studies; 822 patients), respectively. Results: of observational studies confirm that golimumab is an effective therapy for UC in clinical practice.
Sections du résumé
BACKGROUND
Biologics against tumor necrosis factor (anti-TNF) have dramatically changed the management of moderate-to-severe ulcerative colitis (UC). In pivotal clinical trials, golimumab showed efficacy as induction and maintenance therapy in anti-TNF naïve UC patients. However, confirmatory data on effectiveness in the real world setting are needed.
AIM
to summarize recent evidence on the effectiveness of golimumab in observational real-world studies.
METHODS
A literature search was conducted using Medline, Embase, and congresses databases for English language articles or abstracts on the effectiveness of golimumab published between January 1, 2014 and May 15, 2018. Pooled short-term (6-14 weeks) and mid- and long-term (24-54 weeks) clinical response and remission rates were calculated.
RESULTS
24 abstracts were included; of those 8 were published full-text articles and 16 were abstracts from medical conferences. Overall, pooled short-term clinical response and remission rates were 59.3% (range 35-85.5%; 13 studies; 1429 patients) and 35.9% (range 14-51.7%; 9 studies; 666 patients), respectively. Pooled mid- and long-term clinical response and remission rates were 60.3% (range 37.1-89.5%; 4 studies; 356 patients) and 39.2% (range 12-84%; 8 studies; 822 patients), respectively.
CONCLUSIONS
Results: of observational studies confirm that golimumab is an effective therapy for UC in clinical practice.
Identifiants
pubmed: 30555013
pii: S1590-8658(18)31221-0
doi: 10.1016/j.dld.2018.11.002
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Tumor Necrosis Factor-alpha
0
golimumab
91X1KLU43E
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
327-334Informations de copyright
Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.